Adrian Blanco-Gomez

Adrian Blanco-Gomez

Auto-generated profile, based on publicly available information

Adrian Blanco-Gomez

Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, 37007 Salamanca, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Cancer Cell
Verified
Journal Article
Open access
CHColin Hutton
Colin Hutton
FHFelix Heider
Felix Heider
ABAdrian Blanco-Gomez
Adrian Blanco-Gomez
ABAntonia Banyard
Antonia Banyard
AKAlexander Kononov
Alexander Kononov
CJClaus Jørgensen
Claus Jørgensen
Fibroblasts display extensive transcriptional heterogeneity, yet functional annotation and characterization of their heterocellular relationships remains incomplete. Using mass cytometry, we chart the stromal composition of 18 murine tissues and 5 spontaneous tumor models, with an emphasis on mesenchymal phenotypes. This analysis reveals extensive stromal heterogeneity across tissues and tumors, and identifies coordinated relationships between mesenchymal and immune cell subsets in pancreatic ductal adenocarcinoma. Expression of CD105 demarks two stable and functionally distinct pancreatic fibroblast lineages, which are also identified in murine and human healthy tissues and tumors. Whereas CD105-positive pancreatic fibroblasts are permissive for tumor growth in vivo, CD105-negative fibroblasts are highly tumor suppressive. This restrictive effect is entirely dependent on functional adaptive immunity. Collectively, these results reveal two functionally distinct pancreatic fibroblast lineages and highlight the importance of mesenchymal and immune cell interactions in restricting tumor growth.

24 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
VPVictoria S. Pelly
Victoria S. Pelly
AMAgrin Moeini
Agrin Moeini
LRLisanne Roelofsen
Lisanne Roelofsen
Eduardo BonavitaEduardo Bonavita
Eduardo Bonavita
CBCharlotte R. Bell
Charlotte R. Bell
SZSantiago Zelenay
Santiago Zelenay
Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX2/PGE2/EP2-4 pathway with widely used nonsteroidal and steroidal anti-inflammatory drugs synergized with ICB in mouse cancer models. We exploited a bilateral surgery model to distinguish responders from nonresponders shortly after treatment and identified acute IFNγ-driven transcriptional remodeling in responder mice, which was also associated with patient benefit to ICB. Monotherapy with COX2 inhibitors or EP2-4 PGE2 receptor antagonists rapidly induced this response program and, in combination with ICB, increased the intratumoral accumulation of effector T cells. Treatment of patient-derived tumor fragments from multiple cancer types revealed a similar shift in the tumor inflammatory environment to favor T-cell activation. Our findings establish the COX2/PGE2/EP2-4 axis as an independent immune checkpoint and a readily translatable strategy to rapidly switch the tumor inflammatory profile from cold to hot. Significance: Through performing in-depth profiling of mice and human tumors, this study identifies mechanisms by which anti-inflammatory drugs rapidly alter the tumor immune landscape to enhance tumor immunogenicity and responses to immune checkpoint inhibitors. See related commentary by Melero et al., p. 2372. This article is highlighted in the In This Issue feature, p. 2355

27 March 2017 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
Javier CañuetoJavier Cañueto
Javier Cañueto
ECE. Cardeñoso
E. Cardeñoso
JGJuan Garcia
Juan Garcia
ÁSÁ. Santos-Briz
Á. Santos-Briz
ACAndres Castellanos-Martín
Andres Castellanos-Martín
CRC. Román-Curto
C. Román-Curto

31 May 2016 in BioEssays
Verified
Journal Article
Open access
PDF file
ABAdrián Blanco‐Gómez
Adrián Blanco‐Gómez
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
MSMaría del Mar Sáez‐Freire
María del Mar Sáez‐Freire
LHLourdes Hontecillas‐Prieto
Lourdes Hontecillas‐Prieto
Jian-Hua MaoJian-Hua Mao
Jian-Hua Mao
JPJesús Pérez-Losada
Jesús Pérez-Losada
Diseases of complex origin have a component of quantitative genetics that contributes to their susceptibility and phenotypic variability. However, after several studies, a major part of the genetic component of complex phenotypes has still not been found, a situation known as “missing heritability.” Although there have been many hypotheses put forward to explain the reasons for the missing heritability, its definitive causes remain unknown. Complex diseases are caused by multiple intermediate phenotypes involved in their pathogenesis and, very often, each one of these intermediate phenotypes also has a component of quantitative inheritance. Here we propose that at least part of the missing heritability can be explained by the genetic component of intermediate phenotypes that is not detectable at the level of the main complex trait. At the same time, the identification of the genetic component of intermediate phenotypes provides an opportunity to identify part of the missing heritability of complex diseases.

21 February 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
ACAndres Castellanos-Martín
Andres Castellanos-Martín
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
MSMaría del Mar Sáez-Freire
María del Mar Sáez-Freire
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
LHLourdes Hontecillas-Prieto
Lourdes Hontecillas-Prieto
JPJesús Pérez-Losada
Jesús Pérez-Losada
An essential question in cancer is why individuals with the same disease have different clinical outcomes. Progress toward a more personalized medicine in cancer patients requires taking into account the underlying heterogeneity at different molecular levels. Here, we present a model in which there are complex interactions at different cellular and systemic levels that account for the heterogeneity of susceptibility to and evolution of ERBB2-positive breast cancers. Our model is based on our analyses of a cohort of mice that are characterized by heterogeneous susceptibility to ERBB2-positive breast cancers. Our analysis reveals that there are similarities between ERBB2 tumors in humans and those of backcross mice at clinical, genomic, expression, and signaling levels. We also show that mice that have tumors with intrinsically high levels of active AKT and ERK are more resistant to tumor metastasis. Our findings suggest for the first time that a site-specific phosphorylation at the serine 473 residue of AKT1 modifies the capacity for tumors to disseminate. Finally, we present two predictive models that can explain the heterogeneous behavior of the disease in the mouse population when we consider simultaneously certain genetic markers, liver cell signaling and serum biomarkers that are identified before the onset of the disease. Considering simultaneously tumor pathophenotypes and several molecular levels, we show the heterogeneous behavior of ERBB2-positive breast cancer in terms of disease progression. This and similar studies should help to better understand disease variability in patient populations.

1 May 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MSMaría del Mar Sáez-Freire
María del Mar Sáez-Freire
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
AGAurora Gomez-Vecino
Aurora Gomez-Vecino
JGJulie Milena Galvis-Jiménez
Julie Milena Galvis-Jiménez
JPJesús Pérez-Losada
Jesús Pérez-Losada